Trial Profile
A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in participants with Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 28 Jun 2012 According to the EudraCT record, this trial has prematurely ended.
- 28 Jun 2012 New trial record